Monopar Therapeutics 8-K

What Happened

• On May 19, 2026, Monopar Therapeutics (MNPR) filed a Form 8-K (Item 7.01) to disclose a press release announcing the presentation of results from the Phase 2 ALXN1840‑WD‑204 study.
• The company reported that ALXN1840 (tiomolibdate choline) improves copper balance in patients with Wilson disease. The press release is furnished as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: May 19, 2026 (Form 8-K, Item 7.01 — Regulation FD Disclosure).
• Study: Phase 2 ALXN1840‑WD‑204; investigational medicine: ALXN1840 (tiomolibdate choline).
• Disclosure format: Results announced via press release; press release included as Exhibit 99.1 and incorporated by reference.

Why It Matters

• This clinical update signals progress in Monopar’s development program for ALXN1840 in Wilson disease, a rare disorder of copper metabolism.
• For investors, successful Phase 2 results can affect the company’s clinical outlook and future development milestones; the 8-K is a formal, public disclosure of those clinical findings.
• The filing does not include financial metrics or other operational changes; investors should review the full press release (Exhibit 99.1) and future company filings for more detailed data and next steps.